TY - JOUR
T1 - Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools
AU - Gerratana, Lorenzo
AU - Davis, Andrew A.
AU - Polano, Maurizio
AU - Zhang, Qiang
AU - Shah, Ami N.
AU - Lin, Chenyu
AU - Basile, Debora
AU - Toffoli, Giuseppe
AU - Wehbe, Firas
AU - Puglisi, Fabio
AU - Behdad, Amir
AU - Platanias, Leonidas C.
AU - Gradishar, William J.
AU - Cristofanilli, Massimo
N1 - Funding Information:
AAD reports non-financial support from Menarini Silicon Biosystems, outside the submitted work; LG reports non-financial support from Menarini Silicon Biosystems, personal fees from Lilly, outside the submitted work; MC reports grants from National Institutes of Health , during the conduct of the study; personal fees from Pfizer, personal fees from Merus, personal fees from Novartis, personal fees from CytoDyn, outside the submitted work; FP reports grants from AstraZeneca , grants from Eisai, outside the submitted work; all other authors declare no conflict of interest.
Funding Information:
Lynn Sage Cancer Research Foundation, OncoSET Precision Medicine Program, and REDCap support was funded in part by a Clinical and Translational Science Award (CTSA) grant from the National Institutes of Health UL1TR001422 .
Publisher Copyright:
© 2020 The Author(s)
PY - 2021/1
Y1 - 2021/1
N2 - Background: Liquid biopsy provides real-time data about prognosis and actionable mutations in metastatic breast cancer (MBC). The aim of this study was to explore the combination of circulating tumour DNA (ctDNA) analysis and circulating tumour cells (CTCs) enumeration in estimating target organs more susceptible to MBC involvement. Methods: This retrospective study analysed 88 MBC patients characterised for both CTCs and ctDNA at baseline. CTCs were isolated through the CellSearch kit, while ctDNA was analysed using the Guardant360 NGS-based assay. Sites of disease were collected on the basis of imaging. Associations were explored both through uni- and multivariate logistic regression and Fisher's exact test and the random forest machine learning algorithm. Results: After multivariate logistic regression, ESR1 mutation was the only significant factor associated with liver metastases (OR 8.10), while PIK3CA was associated with lung localisations (OR 3.74). CTC enumeration was independently associated with bone metastases (OR 10.41) and TP53 was associated with lymph node localisations (OR 2.98). The metastatic behaviour was further investigated through a random forest machine learning algorithm. Bone involvement was described by CTC enumeration and alterations in ESR1, GATA3, KIT, CDK4 and ERBB2, while subtype, CTC enumeration, inflammatory BC diagnosis, ESR1 and KIT aberrations described liver metastases. PIK3CA, MET, AR, CTC enumeration and TP53 were associated with lung organotropism. The model, moreover, showed that AR, CCNE1, ESR1, MYC and CTC enumeration were the main drivers in HR positive MBC metastatic pattern. Conclusions: These results indicate that ctDNA and CTCs enumeration could provide useful insights regarding MBC organotropism, suggesting a possible role for future monitoring strategies that dynamically focus on high-risk organs defined by tumourbiology.
AB - Background: Liquid biopsy provides real-time data about prognosis and actionable mutations in metastatic breast cancer (MBC). The aim of this study was to explore the combination of circulating tumour DNA (ctDNA) analysis and circulating tumour cells (CTCs) enumeration in estimating target organs more susceptible to MBC involvement. Methods: This retrospective study analysed 88 MBC patients characterised for both CTCs and ctDNA at baseline. CTCs were isolated through the CellSearch kit, while ctDNA was analysed using the Guardant360 NGS-based assay. Sites of disease were collected on the basis of imaging. Associations were explored both through uni- and multivariate logistic regression and Fisher's exact test and the random forest machine learning algorithm. Results: After multivariate logistic regression, ESR1 mutation was the only significant factor associated with liver metastases (OR 8.10), while PIK3CA was associated with lung localisations (OR 3.74). CTC enumeration was independently associated with bone metastases (OR 10.41) and TP53 was associated with lymph node localisations (OR 2.98). The metastatic behaviour was further investigated through a random forest machine learning algorithm. Bone involvement was described by CTC enumeration and alterations in ESR1, GATA3, KIT, CDK4 and ERBB2, while subtype, CTC enumeration, inflammatory BC diagnosis, ESR1 and KIT aberrations described liver metastases. PIK3CA, MET, AR, CTC enumeration and TP53 were associated with lung organotropism. The model, moreover, showed that AR, CCNE1, ESR1, MYC and CTC enumeration were the main drivers in HR positive MBC metastatic pattern. Conclusions: These results indicate that ctDNA and CTCs enumeration could provide useful insights regarding MBC organotropism, suggesting a possible role for future monitoring strategies that dynamically focus on high-risk organs defined by tumourbiology.
KW - Circulating tumour DNA
KW - Circulating tumour cell
KW - Liquid biopsy
KW - Metastatic breast cancer
KW - Organotropism
KW - Precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85097456410&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2020.11.005
DO - 10.1016/j.ejca.2020.11.005
M3 - Article
C2 - 33307492
AN - SCOPUS:85097456410
SN - 0959-8049
VL - 143
SP - 147
EP - 157
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -